PPT-Dementia and Medication Considerations

Kelly Green Boesen PharmD BCPS CDE Overview of Medication Use Treatment of dementia Treatment of behavioral issues associated with dementia Medications to avoid Treatment of Dementia Cholinesterase inhibitors. Analysis of dementia prevalence rates by Delo itte Access Economics reveal coastal and regional NSW will continue to bear the brunt of increasing dementia prevalence rates while the metropolitan areas of the State will also experience a steady incre Head, School of Physiotherapy and Exercise Science, email . Keith.Hill@Curtin.edu.au. Gippsland Forum: Falls prevention for people with dementia (Sept 2014). Falls and dementia: . Epidemiology and interventions. Behavioral . Problems in Patients with End Stage Dementia. Clinical Features in Late Stage Dementia. Alzheimer's – Delusions, agitation. Frontotemporal - Personality changes, disinhibition, Impulsivity. Dr. Cynthia Hadfield, . Pharm.D. .. Director of Pharmacy for Employee, LTC & Retail Pharmacies . Lead Clinical Pharmacist, Geriatric Specialist. Citizens Memorial Healthcare. Dr. Hadfield has no financial, other relationship or other support from the pharmaceutical industry. Colleen O’Connell, . PharmD. TMC Pharmacist. September 25, 2016. Objectives. Describe potential medication concerns with ostomies. List factors that influence medication availability and absorption with ostomies. Dr. Cynthia Hadfield, . Pharm.D. .. Director of Pharmacy for Employee, LTC & Retail Pharmacies . Lead Clinical Pharmacist, Geriatric Specialist. Citizens Memorial Healthcare. Dr. Hadfield has no financial, other relationship or other support from the pharmaceutical industry. Chris Perkins. Alzheimers NZ Conference. 04/11/16. Increased life expectancy. Challenge of diagnosing dementia. Risk reduction. Management . Life expectancy. Schizophrenia. Life expectancy lags by 12 years in women and 15 years in men with schizophrenia (Casey et al , 2011) Some others say 20 years difference.. Colleen O’Connell, . PharmD. TMC Pharmacist. September 25, 2016. Objectives. Describe potential medication concerns with ostomies. List factors that influence medication availability and absorption with ostomies. Laura J. Fochtmann, MD, . MBI. Distinguished Service Professor, Departments of Psychiatry, Pharmacological Sciences and Biomedical Informatics, Stony Brook University. Medical Editor, Practice Guidelines. Fighting the Stigma. Jeffrey Quamme . Executive Director, Connecticut Certification Board. 2018 UVU Conference. Orem, Utah. Our Goals For Today. Understand the history of MAT for Opioid Use Disorders. Dr. Cynthia Hadfield, . Pharm.D. .. Director of Pharmacy for Employee, LTC & Retail Pharmacies . Lead Clinical Pharmacist, Geriatric Specialist. Citizens Memorial Healthcare. Dr. Hadfield has no financial, other relationship or other support from the pharmaceutical industry. Dr. Cynthia Hadfield, . Pharm.D. .. Director of Pharmacy for Employee, LTC & Retail Pharmacies . Lead Clinical Pharmacist, Geriatric Specialist. Citizens Memorial Healthcare. Dr. Hadfield has no financial, other relationship or other support from the pharmaceutical industry. Age (greatest risk factor). Vascular risk factors: HTN, DM, CVD, stroke, smoking, dyslipidemia . Genetics: apo E genotype (late AD), PSEN1, PSEN2, APP (early AD) . Recurrent TBI or head trauma . Drugs: . Human Immunodeciency Virus (HIV) attacks the immune system, making it harder for the body to ght infection and disease. In the advanced stages, HIV can aect the person’s brain